Cargando…
Predictors of survival among Japanese patients receiving first‐line chemoimmunotherapy for advanced non‐small cell lung cancer
BACKGROUND: First‐line chemoimmunotherapy (CIT) has improved overall survival (OS) and progression‐free survival (PFS) outcomes among patients with non‐small cell lung cancer (NSCLC). The immunological and nutritional statuses of patients fluctuate during treatment using immune checkpoint inhibitors...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779203/ https://www.ncbi.nlm.nih.gov/pubmed/33124197 http://dx.doi.org/10.1111/1759-7714.13720 |
_version_ | 1783631287367499776 |
---|---|
author | Ogura, Yuri Kataoka, Nobutaka Kunimatsu, Yusuke Tachibana, Yusuke Sugimoto, Takumi Tani, Nozomi Sato, Izumi Hirose, Kazuki Kato, Daishiro Takeda, Takayuki |
author_facet | Ogura, Yuri Kataoka, Nobutaka Kunimatsu, Yusuke Tachibana, Yusuke Sugimoto, Takumi Tani, Nozomi Sato, Izumi Hirose, Kazuki Kato, Daishiro Takeda, Takayuki |
author_sort | Ogura, Yuri |
collection | PubMed |
description | BACKGROUND: First‐line chemoimmunotherapy (CIT) has improved overall survival (OS) and progression‐free survival (PFS) outcomes among patients with non‐small cell lung cancer (NSCLC). The immunological and nutritional statuses of patients fluctuate during treatment using immune checkpoint inhibitors, and are closely related to treatment outcomes. However, it is unclear whether these markers are significant in patients who are receiving CIT. METHODS: This retrospective single‐center study evaluated 34 consecutive Japanese patients with NSCLC who were treated using first‐line CIT. Previously reported markers that reflect immunological and nutritional statuses were evaluated at three time points: at the start of CIT, after three weeks, and at the end of induction therapy. RESULTS: The median PFS was 7.2 months (95% confidence interval: 6.3 months–not reached) and the median OS was not reached (95% confidence interval: 9.6 months–not reached). The PFS duration was significantly associated with the baseline neutrophil‐to‐lymphocyte ratio and the three‐week values for the modified Glasgow prognostic score, C‐reactive protein‐albumin ratio, prognostic nutrition index, and advanced lung cancer inflammation index. The OS duration was significantly associated with the pre‐treatment values for the neutrophil‐to‐lymphocyte ratio and advanced lung cancer inflammation index, as well as the prognostic nutrition index at the end of induction therapy. CONCLUSIONS: Immunological and nutritional markers could be useful for predicting the outcomes of CIT for Japanese patients with advanced non‐small cell lung cancer. The timing of their evaluation may also be important. KEY POINTS: SIGNIFICANT FINDINGS OF THE STUDY: Overall survival in patients receiving first‐line chemoimmunotherapy for advanced lung cancer were associated with pretreatment values of neutrophil‐to‐lymphocyte ratio, advanced lung cancer inflammation index, and the prognostic nutrition index at the end of induction therapy. WHAT THIS STUDY ADDS: Repetitive evaluation of immunological and nutritional markers may be useful for guiding prognostication and treatment selection for Japanese patients with advanced lung cancer. |
format | Online Article Text |
id | pubmed-7779203 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley & Sons Australia, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-77792032021-01-08 Predictors of survival among Japanese patients receiving first‐line chemoimmunotherapy for advanced non‐small cell lung cancer Ogura, Yuri Kataoka, Nobutaka Kunimatsu, Yusuke Tachibana, Yusuke Sugimoto, Takumi Tani, Nozomi Sato, Izumi Hirose, Kazuki Kato, Daishiro Takeda, Takayuki Thorac Cancer Original Articles BACKGROUND: First‐line chemoimmunotherapy (CIT) has improved overall survival (OS) and progression‐free survival (PFS) outcomes among patients with non‐small cell lung cancer (NSCLC). The immunological and nutritional statuses of patients fluctuate during treatment using immune checkpoint inhibitors, and are closely related to treatment outcomes. However, it is unclear whether these markers are significant in patients who are receiving CIT. METHODS: This retrospective single‐center study evaluated 34 consecutive Japanese patients with NSCLC who were treated using first‐line CIT. Previously reported markers that reflect immunological and nutritional statuses were evaluated at three time points: at the start of CIT, after three weeks, and at the end of induction therapy. RESULTS: The median PFS was 7.2 months (95% confidence interval: 6.3 months–not reached) and the median OS was not reached (95% confidence interval: 9.6 months–not reached). The PFS duration was significantly associated with the baseline neutrophil‐to‐lymphocyte ratio and the three‐week values for the modified Glasgow prognostic score, C‐reactive protein‐albumin ratio, prognostic nutrition index, and advanced lung cancer inflammation index. The OS duration was significantly associated with the pre‐treatment values for the neutrophil‐to‐lymphocyte ratio and advanced lung cancer inflammation index, as well as the prognostic nutrition index at the end of induction therapy. CONCLUSIONS: Immunological and nutritional markers could be useful for predicting the outcomes of CIT for Japanese patients with advanced non‐small cell lung cancer. The timing of their evaluation may also be important. KEY POINTS: SIGNIFICANT FINDINGS OF THE STUDY: Overall survival in patients receiving first‐line chemoimmunotherapy for advanced lung cancer were associated with pretreatment values of neutrophil‐to‐lymphocyte ratio, advanced lung cancer inflammation index, and the prognostic nutrition index at the end of induction therapy. WHAT THIS STUDY ADDS: Repetitive evaluation of immunological and nutritional markers may be useful for guiding prognostication and treatment selection for Japanese patients with advanced lung cancer. John Wiley & Sons Australia, Ltd 2020-10-30 2021-01 /pmc/articles/PMC7779203/ /pubmed/33124197 http://dx.doi.org/10.1111/1759-7714.13720 Text en © 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Ogura, Yuri Kataoka, Nobutaka Kunimatsu, Yusuke Tachibana, Yusuke Sugimoto, Takumi Tani, Nozomi Sato, Izumi Hirose, Kazuki Kato, Daishiro Takeda, Takayuki Predictors of survival among Japanese patients receiving first‐line chemoimmunotherapy for advanced non‐small cell lung cancer |
title | Predictors of survival among Japanese patients receiving first‐line chemoimmunotherapy for advanced non‐small cell lung cancer |
title_full | Predictors of survival among Japanese patients receiving first‐line chemoimmunotherapy for advanced non‐small cell lung cancer |
title_fullStr | Predictors of survival among Japanese patients receiving first‐line chemoimmunotherapy for advanced non‐small cell lung cancer |
title_full_unstemmed | Predictors of survival among Japanese patients receiving first‐line chemoimmunotherapy for advanced non‐small cell lung cancer |
title_short | Predictors of survival among Japanese patients receiving first‐line chemoimmunotherapy for advanced non‐small cell lung cancer |
title_sort | predictors of survival among japanese patients receiving first‐line chemoimmunotherapy for advanced non‐small cell lung cancer |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779203/ https://www.ncbi.nlm.nih.gov/pubmed/33124197 http://dx.doi.org/10.1111/1759-7714.13720 |
work_keys_str_mv | AT ogurayuri predictorsofsurvivalamongjapanesepatientsreceivingfirstlinechemoimmunotherapyforadvancednonsmallcelllungcancer AT kataokanobutaka predictorsofsurvivalamongjapanesepatientsreceivingfirstlinechemoimmunotherapyforadvancednonsmallcelllungcancer AT kunimatsuyusuke predictorsofsurvivalamongjapanesepatientsreceivingfirstlinechemoimmunotherapyforadvancednonsmallcelllungcancer AT tachibanayusuke predictorsofsurvivalamongjapanesepatientsreceivingfirstlinechemoimmunotherapyforadvancednonsmallcelllungcancer AT sugimototakumi predictorsofsurvivalamongjapanesepatientsreceivingfirstlinechemoimmunotherapyforadvancednonsmallcelllungcancer AT taninozomi predictorsofsurvivalamongjapanesepatientsreceivingfirstlinechemoimmunotherapyforadvancednonsmallcelllungcancer AT satoizumi predictorsofsurvivalamongjapanesepatientsreceivingfirstlinechemoimmunotherapyforadvancednonsmallcelllungcancer AT hirosekazuki predictorsofsurvivalamongjapanesepatientsreceivingfirstlinechemoimmunotherapyforadvancednonsmallcelllungcancer AT katodaishiro predictorsofsurvivalamongjapanesepatientsreceivingfirstlinechemoimmunotherapyforadvancednonsmallcelllungcancer AT takedatakayuki predictorsofsurvivalamongjapanesepatientsreceivingfirstlinechemoimmunotherapyforadvancednonsmallcelllungcancer |